Vigonvita Life Sciences Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	11.83	199.65
Revenue Growth (YoY)	-94.07%	-
Cost of Revenue	8.35	6.01
Gross Profit	3.49	193.64
Selling, General & Admin	69.39	52.51
Research & Development	134.86	131.3
Operating Expenses	207.15	186.39
Operating Income	-203.66	7.25
Interest Expense	-16.16	-7.2
Interest & Investment Income	0.71	1.79
Currency Exchange Gain (Loss)	0.24	0.25
Other Non Operating Income (Expenses)	1.21	4.34
EBT Excluding Unusual Items	-217.67	6.43
Gain (Loss) on Sale of Investments	0.22	-
Gain (Loss) on Sale of Assets	-0.04	-
Other Unusual Items	-0.16	-
Pretax Income	-217.64	6.43
Earnings From Continuing Operations	-217.64	6.43
Minority Interest in Earnings	6.24	5.66
Net Income	-211.4	12.09
Net Income to Common	-211.4	12.09
Shares Outstanding (Basic)	146	145
Shares Outstanding (Diluted)	146	145
Shares Change (YoY)	0.69%	-
EPS (Basic)	-1.45	0.08
EPS (Diluted)	-1.45	0.08
Free Cash Flow	-186.53	-56.05
Free Cash Flow Per Share	-1.28	-0.39
Gross Margin	29.47%	96.99%
Operating Margin	-1721.30%	3.63%
Profit Margin	-1786.71%	6.05%
Free Cash Flow Margin	-1576.46%	-28.07%
EBITDA	-183.23	14.12
EBITDA Margin	-	7.07%
D&A For EBITDA	20.44	6.87
EBIT	-203.66	7.25
EBIT Margin	-	3.63%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.